We are live on ! Find out more
ACM

Asymmetry Capital Management Portfolio holdings

AUM $188M
1-Year Est. Return 44.72%
This Fund
S&P 500
This Quarter Est. Return
+3.13%
1 Year Est. Return
+44.72%
3 Year Est. Return
+299.95%
5 Year Est. Return
+628.83%
10 Year Est. Return
–
AUM
$145M
AUM Growth
-$47.9M
Cap. Flow
-$43.6M
Cap. Flow %
-29.96%
Top 10 Hldgs %
61.57%
Holding
40
New
11
Increased
4
Reduced
15
Closed
10

Top Buys

Rank Stock Value
1
CNC icon
Centene
CNC
+$11.3M
2
ACRS icon
Aclaris Therapeutics
ACRS
+$7.17M
3
ALKS icon
Alkermes
ALKS
+$6.79M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$5.41M
5
KYMR icon
Kymera Therapeutics
KYMR
+$5.36M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$11.6M
2
UNH icon
UnitedHealth
UNH
+$10.9M
3
NSTG
NanoString Technologies, Inc.
NSTG
+$9.37M
4
KURA icon
Kura Oncology
KURA
+$7.84M
5
RCUS icon
Arcus Biosciences
RCUS
+$6.64M

Sector Composition

Rank Sector Weight
1 Healthcare 99.4%
2 Financials 0.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MCRB icon
26
Seres Therapeutics
MCRB
$48.9M
$1.51M 1.04%
+3,163
New +$1.33M
VERV
27
DELISTED
Verve Therapeutics
VERV
$1.49M 1.03%
+24,790
New +$1.03M
RGLS
28
DELISTED
Regulus Therapeutics
RGLS
$1.18M 0.81%
145,078
-53,469
-27% -$597K
BLSA
29
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$877K 0.6%
83,277
+900
+1% +$9.32K
DMRA
30
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.84B
$308K 0.21%
2,439
-2,102
-46% -$286K
KURA icon
31
Kura Oncology
KURA
$850M
– –
-277,468
Closed -$7.84M
RCUS icon
32
Arcus Biosciences
RCUS
$3.64B
– –
-236,494
Closed -$6.64M
SAGE
33
DELISTED
Sage Therapeutics
SAGE
– –
-79,650
Closed -$5.96M
UNH icon
34
UnitedHealth
UNH
$370B
– –
-29,357
Closed -$10.9M
VRTX icon
35
Vertex Pharmaceuticals
VRTX
$126B
– –
-53,855
Closed -$11.6M
SEEL
36
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
– –
-115
Closed -$2.2M
RNLX
37
DELISTED
Renalytix plc American Depositary Shares
RNLX
– –
-160,969
Closed -$4.13M
NSTG
38
DELISTED
NanoString Technologies, Inc.
NSTG
– –
-142,530
Closed -$9.37M
JNCE
39
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
– –
-520,858
Closed -$5.35M
TPTX
40
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
– –
-11,873
Closed -$1.12M
1
2

Similar funds

FAC
Forrestal Agricultural Corporation Princeton, New Jersey $183M AUM
SWM
Strategic Wealth Management Kirkland, Washington $202M AUM 9.35% 1-Year Est. Return
MC
MRJ Capital New York $173M AUM 31.99% 1-Year Est. Return
KM
Kylin Management New York $173M AUM 39.51% 1-Year Est. Return
TI
Truehand Inc Strafford, New Hampshire $171M AUM 25.9% 1-Year Est. Return
GC
Grace Capital Quincy, Massachusetts $168M AUM 21.6% 1-Year Est. Return
REMS
Real Estate Management Services $167M AUM 37.69% 1-Year Est. Return
NM
Nokota Management New York $165M AUM

Asymmetry Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, Asymmetry Capital Management held 40 positions worth $145M, down 25% from $193M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Asymmetry Capital Management withdrew a net $43.6M in Q2 2021, closing 10 positions and reducing 15 holdings. Its most notable exit was Vertex Pharmaceuticals, an estimated $11.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.

Against the trend, Asymmetry Capital Management opened a new position in Centene worth $12M.

  • Asymmetry Capital Management's largest Q2 2021 buy was Centene: 164,489 shares worth $12M.
  • Asymmetry Capital Management added most to Mirati Therapeutics, Inc. Common Stock in Q2 2021, an estimated $5.41M increase.
  • Asymmetry Capital Management's biggest Q2 2021 reduction was Guardant Health, cutting an estimated $5.04M.
  • Asymmetry Capital Management fully exited Vertex Pharmaceuticals in Q2 2021, selling an estimated $11.6M.
  • Asymmetry Capital Management's ten largest holdings make up 62% of its $145M portfolio in Q2 2021.
  • Asymmetry Capital Management opened 11 new positions and closed 10 in Q2 2021.
  • Asymmetry Capital Management's portfolio value fell 25% quarter-over-quarter to $145M.

Based on Asymmetry Capital Management's 13F filing for Q2 2021, filed 28 Jul 2021.